Full-Time

Customer Experience Representative

Remote, Canada, PT/MT

Posted on 8/30/2024

Biorender

Biorender

201-500 employees

Online platform for creating scientific illustrations

No salary listed

Entry, Junior

Remote in Canada

Open to candidates in Canada living in Pacific and Mountain timezones.

Category
Customer Experience & Support
Customer Experience
Required Skills
Sales
Zendesk
Customer Service
Requirements
  • 1+ years of experience in customer service (ideally in a SaaS or technology company)
  • Bachelor's degree in the life sciences
  • Strong interpersonal skills
  • Experience using Zendesk, Intercom, or other customer support platform
  • Interest / knowledge in the life sciences
  • Self-starter with ability to thrive in a fast-paced environment
  • Strong attention to detail
  • Legally authorized to work in Canada, located in MST and PST time zone, and able to work some weekends
Responsibilities
  • Monitor and manage customer chat requests, providing real-time customer support and resolving any technical issues
  • Liaise with the sales and product team to provide users the best possible experience
  • Relay feedback from users to the product team, ensuring we address any technical glitches or bugs
  • Understand user satisfaction and track NPS scores
  • Monitor our company phone line and support email, responding to queries when they happen

BioRender provides an online platform that allows scientists and educators to create and share scientific illustrations. The platform features thousands of pre-drawn icons and templates covering over 30 fields in life sciences, enabling users to produce professional and visually appealing figures quickly. Users can customize these icons and templates to fit their specific needs, making it easier to create figures for research papers, presentations, and educational materials. BioRender differentiates itself from competitors by offering a user-friendly interface and a vast library of resources tailored for the life sciences community. The company operates on a subscription-based model, providing various plans to cater to different user needs, including options for larger organizations. The goal of BioRender is to streamline the process of creating scientific illustrations, making it accessible and efficient for researchers and educators.

Company Size

201-500

Company Stage

Series A

Total Funding

$17.2M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for digital communication boosts need for scientific visualization tools.
  • Growing interest in graphical abstracts enhances research visibility and accessibility.
  • Open-access publishing trend increases demand for high-quality, appealing figures.

What critics are saying

  • AI-driven design tools may reduce demand for BioRender's platform.
  • Increased competition from cheaper visualization platforms could erode market share.
  • Potential IP disputes over pre-drawn icons could lead to legal challenges.

What makes Biorender unique

  • BioRender offers a vast library of customizable icons and templates for scientists.
  • The platform provides a user-friendly interface for creating professional scientific figures.
  • BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

5%

2 year growth

5%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.

INACTIVE